Samuel Wadsworth
Directeur Technique/Scientifique/R&D chez ULTRAGENYX PHARMACEUTICAL INC.
Fortune : 54 206 $ au 31/05/2024
Profil
Samuel C.
Wadsworth is an Independent Director at Precision BioSciences, Inc. since 2021 and the Chief Scientific Officer at Ultragenyx Pharmaceutical, Inc. since 2017.
Previously, he worked as the Director-Molecular Biology at Genzyme Corp.
from 2010 to 2013 and as the Chief Scientific Officer at Dimension Therapeutics, Inc. from 2013 to 2017.
Dr. Wadsworth holds a doctorate degree from The University of Chicago and an undergraduate degree from Southern Illinois University.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
| 04/06/2024 | 4 202 ( 0,06% ) | 54 206 $ | 31/05/2024 |
Postes actifs de Samuel Wadsworth
| Sociétés | Poste | Début |
|---|---|---|
| ULTRAGENYX PHARMACEUTICAL INC. | Directeur Technique/Scientifique/R&D | 01/11/2017 |
| PRECISION BIOSCIENCES, INC. | Directeur/Membre du Conseil | 06/11/2021 |
Anciens postes connus de Samuel Wadsworth
| Sociétés | Poste | Fin |
|---|---|---|
| DIMENSION THERAPEUTICS INC | Directeur Technique/Scientifique/R&D | 01/11/2017 |
Genzyme Corp.
 Genzyme Corp. Medical SpecialtiesHealth Technology Genzyme Corp. engages in development and manufacture of specialty therapeutic, surgical and diagnostic product. It serves in the areas of rare genetic diseases, multiple sclerosis, cardiovascular diseases and endocrinology. The company was founded on June 8, 1981 and is headquartered in Cambridge, MA. | Corporate Officer/Principal | 01/01/2013 |
Sanofi-Aventis U.S. LLC
 Sanofi-Aventis U.S. LLC Pharmaceuticals: MajorHealth Technology Sanofi-Aventis U.S. LLC engages in the provision of pharmaceutical products. It discovers, develops, produces and markets innovative therapies. The firm extensive research and development efforts are focused on health care challenges in cardiology, oncology and internal medicine, as well as metabolic diseases, central nervous system disorders, ophthalmology and vaccines. The company is headquartered in Bridgewater, NJ. | Corporate Officer/Principal | - |
Formation de Samuel Wadsworth
| The University of Chicago | Doctorate Degree |
| Southern Illinois University | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 2 |
|---|---|
| ULTRAGENYX PHARMACEUTICAL INC. | Health Technology |
| PRECISION BIOSCIENCES, INC. | Health Technology |
| Entreprise privées | 3 |
|---|---|
Dimension Therapeutics, Inc.
 Dimension Therapeutics, Inc. BiotechnologyHealth Technology Dimension Therapeutics, Inc. engages in the development of novel treatments for rare diseases. Its activities include discoveries and development of therapeutic products for people living with rare diseases associated wit the liver and caused by genetic mutations. The company was founded by Ben Auspitz in June 20, 2013 and is headquartered in Cambridge, MA. | Health Technology |
Genzyme Corp.
Genzyme Corp. Medical SpecialtiesHealth Technology Genzyme Corp. engages in development and manufacture of specialty therapeutic, surgical and diagnostic product. It serves in the areas of rare genetic diseases, multiple sclerosis, cardiovascular diseases and endocrinology. The company was founded on June 8, 1981 and is headquartered in Cambridge, MA. | Health Technology |
Sanofi-Aventis U.S. LLC
Sanofi-Aventis U.S. LLC Pharmaceuticals: MajorHealth Technology Sanofi-Aventis U.S. LLC engages in the provision of pharmaceutical products. It discovers, develops, produces and markets innovative therapies. The firm extensive research and development efforts are focused on health care challenges in cardiology, oncology and internal medicine, as well as metabolic diseases, central nervous system disorders, ophthalmology and vaccines. The company is headquartered in Bridgewater, NJ. | Health Technology |
